- Conditions
- Metastatic Colorectal Cancer
- Interventions
- 5-Fluorouracil, Bevacizumab, Folinic acid, MEGF0444A, Oxaliplatin, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 3,497
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostate Cancer
- Interventions
- Atkins Diet
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Durham, North Carolina
- Conditions
- Vulvodynia
- Interventions
- Botulinum toxin type A, Placebo
- Biological · Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 8
- States / cities
- Washington D.C., District of Columbia • Miami, Florida • Kansas City, Missouri + 4 more
- Conditions
- Diabetes Mellitus
- Interventions
- BGP-15 100 mg QD, BGP-15 100 mg BID, Placebo BID, BGP-15 200 mg QD, BGP-15 200 mg BID, BGP-15 400 mg QD
- Drug
- Lead sponsor
- N-Gene Research Laboratories, Inc.
- Industry
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 20
- States / cities
- Los Angeles, California • Paramount, California • Tustin, California + 17 more
- Conditions
- Low Grade Glioma
- Interventions
- Vinblastine, Bevacizumab
- Drug
- Lead sponsor
- The Hospital for Sick Children
- Other
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 2 more
- Conditions
- Obesity
- Interventions
- 5 & 2 & 2 Plan, 4 & 2 & 1 Plan
- Other
- Lead sponsor
- Medifast, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 372 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Owings Mills, Maryland
- Conditions
- Breast Cancer
- Interventions
- Everolimus, Placebo, Trastuzumab, Paclitaxel
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 719 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 25
- States / cities
- Mobile, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 21 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2189265, Exenatide, Placebo, Metformin, Pioglitazone
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 978 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 78
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Cathedral City, California + 75 more
- Conditions
- Ocular Hypertension, Open-angle Glaucoma
- Interventions
- AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo, AR-13324 Ophthalmic Solution 0.02% BID
- Drug · Other
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- Up to 99 Years
- Enrollment
- 756 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Bedminster, New Jersey
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Interventions
- docetaxel, placebo, prednisone, bevacizumab, laboratory biomarker analysis
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,050 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut • Chicago, Illinois
- Conditions
- HNSCC
- Interventions
- Motolimod, Nivolumab, Motolimod + Nivolumab
- Drug · Biological · Combination Product
- Lead sponsor
- Presage Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 5
- States / cities
- San Francisco, California • Chicago, Illinois • Winston-Salem, North Carolina + 1 more
- Conditions
- Healthy
- Interventions
- Placebo, RSV preF Protein 50 mcg, RSV preF Protein 150 mcg, Ad26.RSV.preF 1*10^11 vp, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg, Selected Regimen
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 669 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 6
- States / cities
- Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
- Conditions
- Colorectal Adenoma, Stage 0 Colorectal Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8
- Interventions
- Linaclotide, Placebo
- Drug · Other
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 3
- States / cities
- Philadelphia, Pennsylvania • Seattle, Washington
- Conditions
- Plantar Fasciitis
- Interventions
- Botulinum Toxins, Type A, Placebo
- Biological
- Lead sponsor
- Revance Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 5
- States / cities
- Duluth, Georgia • Des Plaines, Illinois • Overland Park, Kansas + 2 more
- Conditions
- Diabetes Type 2
- Interventions
- Technosphere® Insulin Inhalation Powder, 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 677 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 80
- States / cities
- Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more
- Conditions
- Prostate Cancer
- Interventions
- Protein restrictive diet
- Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- Male only
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Diabetic Peripheral Neuropathy
- Interventions
- DS-5565 tablet, pregabalin capsule, Placebo tablet, placebo capsule
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 66 more
- Conditions
- Primary Sjögren's Syndrome
- Interventions
- Baminercept, Placebo
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Palo Alto, California • Hartford, Connecticut + 6 more
- Conditions
- Bariatric Surgery Candidate, Diet Modification
- Interventions
- Dietary modification with introduction of Mankai
- Other
- Lead sponsor
- Cleveland Clinic Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Weston, Florida
- Conditions
- Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
- Interventions
- HLX22, Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine
- Drug
- Lead sponsor
- Shanghai Henlius Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 29
- States / cities
- Anaheim, California • Los Alamitos, California • Greeley, Colorado + 24 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID, Placebo
- Drug
- Lead sponsor
- vTv Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 51
- States / cities
- Scottsdale, Arizona • Little Rock, Arkansas • Granada Hills, California + 44 more
- Conditions
- Hypertension
- Interventions
- carvedilol controlled release/lisinopril, lisinopril + placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 76
- States / cities
- Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 66 more
- Conditions
- Breast Cancer
- Interventions
- Tamoxifen Citrate, Placebo, Digital mammography, immunohistochemistry staining method, pharmacological study, laboratory biomarker analysis, protein expression analysis, pharmacogenomic studies, questionnaire administration, Fine needle aspiration, Quality of Life Assessment
- Drug · Procedure · Other + 1 more
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 25 Years and older · Female only
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2028
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Duarte, California • Aurora, Colorado + 9 more
- Conditions
- Oral Lichen Planus
- Interventions
- Curcuminoids, Placebo
- Drug
- Lead sponsor
- Nita Chainani Wu
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- San Francisco, California